- Email: [email protected]
4940695 Bismuth-containing pharmaceutical compositions
xii
New Patents
An arrangement is provided for the application of an oral pharmaceutical to the mucosa of the oral or nasal cavity, for sustained release there of the drug. The arrangement of the invention comprises a body which has a size and shape suitable for insertion into and retention in the oral or nasal cavity, the body being formed of granules of a higher aliphatic alcohol and a hydrated water soluble hydroxyalkyl cellulose having the drug distributed therethrough. This body is coated with a cellulose derivative which is adherent to the mucosa. As a consequence, upon insertion into the oral or nasal cavity, the body adheres to the mucosa and the drug is there slowly released and absorbed into the body. The arrangement is preferably in the form of a buccal tablet, particularly a kidney shaped buccal tablet. Any drug suitable for oral administration can be used, morphine being preferred. The cellulose derivative which is preferred is hydroxypropyl cellulose. The higher aliphatic alcohol is preferably cetostearyl alcohol, and the water soluble cellulose is preferably hydroxyethyl cellulose.
4940705 N-SUBSTITUTED DERIVATIVE~ OF 1-DESOXYNOJIRIMYCIN AN 1 DESOXYMANNONOJIRIMYC[ AND PHARMACEUTICAL USE Hors Boshagen, Bod Junge, Arnold Paesse Matthias Schuller, Haan, Federal Republic Germany assigned to Bayer Aktiengesellscha N-substituted derivatives of desoxynojirimycin and 1-desoxymannojirimy~ of the formula See Patent for Chemical Structz in which one of R and R' are hydroxyl and | other is hydrogen n is a number from 1 to 6 Rl hydrogen, alkyl or benzyl and R2 is alkyl whi is optionally substituted by an optionally st stituted aryl or by pyridyl, thienyl, fur pyrimidyl, pyrazinyl or quinolyl or R1 is cyc alkyl or R2 is optionally substituted by aryI R2 is a saturated bridged heterocycle or R1 a R2 together can form a heterocyclic ring whic[ optionally substituted. These compounds useful in the treatment of and prophylaxis viral infections.
4940706
4940695 BISMUTH-CONTAINING PHARMACEUTICAL COMPOSITIONS Leila D Coveney, Linda Jones, Jerry Maney assigned to The Procter & Gamble Company Pharmaceutical compositions suitable for oral administration comprising: (a) pharmaceutically-acceptable bismuthcontaining agents such as bismuth subsalicylate; (b) pharmaceutically-acceptable non-ionic cellulose ether polymers such as methylcellulose; and (c) magnesium aluminum silicate. The ratio of bismuth to non-ionic cellulose ether polymer is greater than about 1.5:1. Compositions in the form of liquids containing water are preferred. This invention also relates to methods for treating or preventing disturbances of the gastrointestinal tract in humans or lower animals by orally administering a composition of the present invention.
2 , 4 - D I S U B S T I T U T E D 1,3DIOXOLANES AND PHARMACEUTICAL USE Javier Bartroli, Manuel Anquita, Elena Care ler, Barcelona, Spain assigned to J Uriach & £ SA The present invention describes novel 2. disubstituted 1,3-dioxolanes having the formt I See Patent for Chemical Structure I wherein 1 represents a long chain alkyl group; X is a co~ lent single bond, a carbonyl group, a carbo~ group, a carbamoyl group or a -O-P( dour bondO)(Oz)- group; z is a negative charge when q is zero, or z is an hydrogen atom whet is one; n is an integer from 2 to 10; R2, R3 and I are lower alkyl groups, or R2R3R4N represents an aromatic cyclic ammonium gro~ or R 2 R 3 R 4 N + represents a non-aroma cyclic ammonium group in which two of t groups (R2, R3 or R4) form a non-aromatic ri: together with the quaternary nitrogen atom; a~ A- is a pharmaceutically acceptable anion. The compounds are in vitro inhibitors of the platel aggregation induced by the platelet activati~ factor (PAF) and, thus, useful for the treatme
New Patents
An arrangement is provided for the application of an oral pharmaceutical to the mucosa of the oral or nasal cavity, for sustained release there of the drug. The arrangement of the invention comprises a body which has a size and shape suitable for insertion into and retention in the oral or nasal cavity, the body being formed of granules of a higher aliphatic alcohol and a hydrated water soluble hydroxyalkyl cellulose having the drug distributed therethrough. This body is coated with a cellulose derivative which is adherent to the mucosa. As a consequence, upon insertion into the oral or nasal cavity, the body adheres to the mucosa and the drug is there slowly released and absorbed into the body. The arrangement is preferably in the form of a buccal tablet, particularly a kidney shaped buccal tablet. Any drug suitable for oral administration can be used, morphine being preferred. The cellulose derivative which is preferred is hydroxypropyl cellulose. The higher aliphatic alcohol is preferably cetostearyl alcohol, and the water soluble cellulose is preferably hydroxyethyl cellulose.
4940705 N-SUBSTITUTED DERIVATIVE~ OF 1-DESOXYNOJIRIMYCIN AN 1 DESOXYMANNONOJIRIMYC[ AND PHARMACEUTICAL USE Hors Boshagen, Bod Junge, Arnold Paesse Matthias Schuller, Haan, Federal Republic Germany assigned to Bayer Aktiengesellscha N-substituted derivatives of desoxynojirimycin and 1-desoxymannojirimy~ of the formula See Patent for Chemical Structz in which one of R and R' are hydroxyl and | other is hydrogen n is a number from 1 to 6 Rl hydrogen, alkyl or benzyl and R2 is alkyl whi is optionally substituted by an optionally st stituted aryl or by pyridyl, thienyl, fur pyrimidyl, pyrazinyl or quinolyl or R1 is cyc alkyl or R2 is optionally substituted by aryI R2 is a saturated bridged heterocycle or R1 a R2 together can form a heterocyclic ring whic[ optionally substituted. These compounds useful in the treatment of and prophylaxis viral infections.
4940706
4940695 BISMUTH-CONTAINING PHARMACEUTICAL COMPOSITIONS Leila D Coveney, Linda Jones, Jerry Maney assigned to The Procter & Gamble Company Pharmaceutical compositions suitable for oral administration comprising: (a) pharmaceutically-acceptable bismuthcontaining agents such as bismuth subsalicylate; (b) pharmaceutically-acceptable non-ionic cellulose ether polymers such as methylcellulose; and (c) magnesium aluminum silicate. The ratio of bismuth to non-ionic cellulose ether polymer is greater than about 1.5:1. Compositions in the form of liquids containing water are preferred. This invention also relates to methods for treating or preventing disturbances of the gastrointestinal tract in humans or lower animals by orally administering a composition of the present invention.
2 , 4 - D I S U B S T I T U T E D 1,3DIOXOLANES AND PHARMACEUTICAL USE Javier Bartroli, Manuel Anquita, Elena Care ler, Barcelona, Spain assigned to J Uriach & £ SA The present invention describes novel 2. disubstituted 1,3-dioxolanes having the formt I See Patent for Chemical Structure I wherein 1 represents a long chain alkyl group; X is a co~ lent single bond, a carbonyl group, a carbo~ group, a carbamoyl group or a -O-P( dour bondO)(Oz)- group; z is a negative charge when q is zero, or z is an hydrogen atom whet is one; n is an integer from 2 to 10; R2, R3 and I are lower alkyl groups, or R2R3R4N represents an aromatic cyclic ammonium gro~ or R 2 R 3 R 4 N + represents a non-aroma cyclic ammonium group in which two of t groups (R2, R3 or R4) form a non-aromatic ri: together with the quaternary nitrogen atom; a~ A- is a pharmaceutically acceptable anion. The compounds are in vitro inhibitors of the platel aggregation induced by the platelet activati~ factor (PAF) and, thus, useful for the treatme